Literature DB >> 16474398

A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation.

Nathaniel M Weathington1, Anneke H van Houwelingen, Brett D Noerager, Patricia L Jackson, Aletta D Kraneveld, F Shawn Galin, Gert Folkerts, Frans P Nijkamp, J Edwin Blalock.   

Abstract

We describe the tripeptide neutrophil chemoattractant N-acetyl Pro-Gly-Pro (PGP), derived from the breakdown of extracellular matrix (ECM), which shares sequence and structural homology with an important domain on alpha chemokines. PGP caused chemotaxis and production of superoxide through CXC receptors, and administration of peptide caused recruitment of neutrophils (PMNs) into lungs of control, but not CXCR2-deficient mice. PGP was generated in mouse lung after exposure to lipopolysaccharide, and in vivo and in vitro blockade of PGP with monoclonal antibody suppressed PMN responses as much as chemokine-specific monoclonal antibody. Extended PGP treatment caused alveolar enlargement and right ventricular hypertrophy in mice. PGP was detectable in substantial concentrations in a majority of bronchoalveolar lavage samples from individuals with chronic obstructive pulmonary disease, but not control individuals. Thus, PGP's activity links degradation of ECM with neutrophil recruitment in airway inflammation, and PGP may be a biomarker and therapeutic target for neutrophilic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474398     DOI: 10.1038/nm1361

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  223 in total

Review 1.  Stress responses affecting homeostasis of the alveolar capillary unit.

Authors:  Rubin M Tuder; Toshinori Yoshida
Journal:  Proc Am Thorac Soc       Date:  2011-11

Review 2.  The impact of the extracellular matrix on inflammation.

Authors:  Lydia Sorokin
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

Review 3.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model.

Authors:  Jonathan P Jacobs; Adriana Ortiz-Lopez; James J Campbell; Craig J Gerard; Diane Mathis; Christophe Benoist
Journal:  Arthritis Rheum       Date:  2010-07

6.  Uric acid promotes an acute inflammatory response to sterile cell death in mice.

Authors:  Hajime Kono; Chun-Jen Chen; Fernando Ontiveros; Kenneth L Rock
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

7.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.

Authors:  Mikell Paige; Kan Wang; Marie Burdick; Sunhye Park; Josiah Cha; Erin Jeffery; Nicholas Sherman; Y Michael Shim
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

Review 9.  Matrix remodeling in chronic lung diseases.

Authors:  Bon-Hee Gu; Matthew C Madison; David Corry; Farrah Kheradmand
Journal:  Matrix Biol       Date:  2018-03-17       Impact factor: 11.583

10.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.